NASDAQ:NTLAIntellia Therapeutics Stock Price, Forecast & News

Intellia Therapeutics' stock was trading at $12.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTLA stock has increased by 87.2% and is now trading at $23.81. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intellia Therapeutics.

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intellia Therapeutics.

Intellia Therapeutics Inc (NASDAQ:NTLA) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.24. The firm earned $12.92 million during the quarter, compared to analysts' expectations of $21.98 million. Intellia Therapeutics had a negative net margin of 239.98% and a negative return on equity of 40.89%. The business's revenue was up 23.8% on a year-over-year basis. During the same period last year, the firm earned ($0.49) earnings per share. View Intellia Therapeutics' earnings history.

6 equities research analysts have issued 12 month target prices for Intellia Therapeutics' stock. Their forecasts range from $20.00 to $57.50. On average, they expect Intellia Therapeutics' share price to reach $28.90 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View analysts' price targets for Intellia Therapeutics.

News coverage about NTLA stock has been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intellia Therapeutics earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news about Intellia Therapeutics.

Intellia Therapeutics saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 10,030,000 shares, a decline of 7.2% from the June 15th total of 10,810,000 shares. Based on an average trading volume of 916,100 shares, the days-to-cover ratio is currently 10.9 days. Approximately 25.1% of the shares of the company are short sold. View Intellia Therapeutics' Current Options Chain.

Some companies that are related to Intellia Therapeutics include Neogen (NEOG), Meridian Bioscience (VIVO), Myriad Genetics (MYGN), Heska (HSKA), Quotient (QTNT), Lantheus (LNTH), Vermillion (VRML), Oxford Immunotec Global (OXFD), Celldex Therapeutics (CLDX), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), ImmuCell (ICCC), Arca Biopharma (ABIO) and Akers Biosciences (AKER). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Square (SQ), InVitae (NVTA), Advanced Micro Devices (AMD), Cisco Systems (CSCO) and Sangamo Therapeutics (SGMO).

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NTLA stock can currently be purchased for approximately $23.81.

Intellia Therapeutics has a market capitalization of $1.22 billion and generates $43.10 million in revenue each year. The company earns $-99,530,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.

The official website for Intellia Therapeutics is www.intelliatx.com.

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]